Document is current
Any future updates will be listed below
-
Authors
Cornell, Lucy J
Harrold, Caroline L
Holliman, Susannah
Tsang, Felice
Gosden, Matthew E
Hanssen, Lars L P https://orcid.org/0000-0002-2551-2278
Stolper, Rosa
Downes, Damien J https://orcid.org/0000-0002-5034-0869
Biggs, Daniel
Preece, Chris
Alghadban, Samy
Sharpe, Jacqueline A
Davies, Benjamin https://orcid.org/0000-0003-3623-600X
Sloane-Stanley, Jacqueline A
Hughes, Jim R https://orcid.org/0000-0002-8955-7256
Higgs, Douglas R https://orcid.org/0000-0003-3579-8705
Kassouf, Mira T https://orcid.org/0000-0002-9781-921X
-
Funding
Funding for this research was provided by:
Wellcome Trust (099684/Z/12/Z)
Wellcome Trust (109110/Z/15/Z)
Wellcome Trust (222843/Z/21/Z)
Wellcome Trust (106130/Z/14/Z)
Wellcome Trust (203141/Z/16/Z)
Wellcome Trust (215111/Z/18/Z)
CAMS | Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2018-I2M-2-002)
UKRI | Medical Research Council (MR/N00969X/1)
UKRI | Medical Research Council (MR/T014067/1)
UKRI | Biotechnology and Biological Sciences Research Council (BB/Y008898/1)
- License Information
-
More Information
Article History
Received: 22 October 2024
Revised: 23 December 2025
Accepted: 21 January 2026
First Online: 16 March 2026
Disclosure and competing interests statement
: JRH is a founder and shareholder of Nucleome Therapeutics; JRH and DJD are paid consultants for Nucleome Therapeutics. JRH holds patents for NG Capture-C. Patent applicant: Oxford University Innovation Limited, Name of inventor(s): James R Hughes and James Davies nos. WO2017068379A1, EP3365464B1 and US10934578B2. Specific aspect of manuscript covered in patent application: NG-CaptureC experiments. These authors declare no other financial or non-financial interests. The remaining authors declare no competing interests.
